Q-omics provides the consensus-scored CNPY3 profile across patient tissues and cancer cell-line models. CNPY3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CNPY3 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, CNPY3 protein abundance shows 21,630 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where CNPY3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNPY3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNPY3 survival associations across molecular data types. CNPY3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNPY3 RNA expression–survival associations across cancer types. High CNPY3 expression shows unfavorable associations in ACC, COAD, KIRC and LGG, but favorable associations in SCLC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CNPY3 RNA expression.
This table summarizes CNPY3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CNPY3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNPY3 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, KIRP, COAD and STAD. The KIRC box plot shows higher CNPY3 RNA expression in tumor versus normal tissue (log2 FC = +0.987, t-test p < 0.001).
This table shows molecular features associated with CNPY3 in patient tissues and cancer cell lines. In patient samples, CNPY3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNPY3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
